Nabriva Therapeutics nabriva.com


Public lists: Pharma Startups (4732)

Nabriva Therapeutics is a biotechnology company focused on developing a class of antibiotics, the pleuromutilins, for the treatment of patients with serious infections caused by multi-drug resistant pathogens.

Nabriva Therapeutics is a biotechnology company focused on developing a class of antibiotics, the pleuromutilins, for the treatment of patients with serious infections caused by multi-drug resistant pathogens.

Company (IPO / Went public)

Phone: +43 (0)1 740 93-0

Fax:

Leberstrasse 20

Vienna, 1110
Austria

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Nabriva Therapeutics $234.3M Sep 18, 2015
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Nabriva Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 11 investors

Competitors

Company Status Description Investors
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
12-epi pleuromutilins Jan 21, 2015 Jul 11, 2017 Patent
Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes Aug 11, 2011 Mar 08, 2016 Patent
Organic compounds Jul 26, 2006 Jan 01, 2013 Patent
Tuberculosis treatment using pleuromutilin derivatives Jun 13, 2007 Jan 03, 2012 Patent
Organic compounds Jan 11, 2007 Oct 19, 2010 Patent
See all 8 patents